Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8912908 | 1.00 | MMP8 (0.53) | MMP8GAAPIN1MEN1NPC1 | |
| Hydrochloric Acid SCHEMBL3449917 | 0.98 | PIN1 (0.51) | MMP8GAAPIN1MEN1NPC1 | |
| SCHEMBL28470487 | 0.86 | MMP8 (0.50) | MMP8GAAPIN1MEN1NPC1 | |
| SCHEMBL5200954 | 0.86 | LMNA (0.50) | MEN1KMT2ASMN1; SMN2CYP1A2CYP2D6 | |
| Hydrazine SCHEMBL27358872 | 0.86 | GAA (0.59) | MMP8GAAMEN1KMT2AKDM4E | |
| SCHEMBL23027214 | 0.85 | GAA (0.62) | MMP8GAAPIN1MEN1KMT2A | |
| SCHEMBL260296 | 0.85 | GAA (0.62) | MMP8GAAPIN1MEN1KMT2A | |
| SCHEMBL5972492 | 0.85 | MMP8 (0.56) | MMP8GAAPIN1MEN1NPC1 | |
| SCHEMBL805646 | 0.85 | GAA (0.62) | MMP8GAAPIN1MEN1KMT2A | |
| SCHEMBL11641330 | 0.84 | ESR1 (0.49) | GAAKMT2ASMN1; SMN2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229801-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| US-10189819-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3408256-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | Takeda Pharmaceutical Company Limited (JP) | 2018-12-05 | — | — | EP | disclosed |
| US-20180030036-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| EP-3229801-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-10-18 | — | — | EP | disclosed |
| WO-2017131221-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017131221-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-03 | — | — | WO | disclosed |
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-1572693-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| WO-2004058762-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-6150335-A | TREATMENT FOR PAIN | ASTRA AB (SE) | 2000-11-21 | — | — | US | disclosed |
| US-5399570-A | Aspartic acid derivatives, and their use for inhibiting platelete aggregation | CASSELLA AKTIENGESELLSCHAFT (DE) | 1995-03-21 | — | — | US | disclosed |
| US-5219886-A | Cardiovascular disorders, analgesics, enzyme inhibitors | SCHERING CORPORATION (US) | 1993-06-15 | — | — | US | disclosed |
| EP-0393441-B1 | MERCAPTO-ACYLAMINO ACIDS | SCHERING CORPORATION (US) | 1993-05-26 | — | — | EP | disclosed |
| EP-0467957-A1 | MERCAPTO-ACYLAMINO ACIDS | SCHERING CORPORATION (US) | 1992-01-29 | — | — | EP | disclosed |
| EP-0393441-A1 | Mercapto-acylamino acids | SCHERING CORPORATION (US) | 1990-10-24 | — | — | EP | disclosed |
| WO-1990012003-A1 | MERCAPTO-ACYLAMINO ACIDS | SCHERING CORPORATION (US) | 1990-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | MAPKAPK2, MAP3K2, MKNK2 | MMP8 900/4885GAA 1556/4885PIN1 2797/4885 |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | GRM7, GRIN2B, GRM1 | MMP8 4696/4885GAA 4545/4885PIN1 1484/4885 |
| US-20180030036-A1 | Factor IXa Inhibitors | F9, TFPI, F12 | MMP8 133/4885GAA 1302/4885PIN1 2450/4885 |
| US-10189819-B2 | Factor IXa inhibitors | F9, TFPI, F12 | MMP8 133/4885GAA 1302/4885PIN1 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.